

PATENT
ATTORNEY DOCKET NO.: TNX98-03-01
Customer No.: 26839

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

OCT 10 2006

In Re Application of:
Ni, Paul et al.

Serial No.: 10/071,962

Filed: February 8, 2002

For: G-CSF RECEPTOR AGONIST
ANTIBODIES AND SCREENING METHODS
THEREFOR

Group Art Unit: 1647

Examiner: L. Spector

APPEAL BRIEF

I. Real Party in Interest

The subject application is owned by Tanox, Inc. of Houston, Tx.

II. Related Appeals and Interferences

There are no other appeals or interferences related to the subject application.

III. Status of the Claims

On July 7, 2006, appellant appealed from the final rejection of claims 31-33, 36-38, 40, 45 and 48-50, claims 1-30, 34-35, and 42-43 having been cancelled, and claims 44, 46-47 having been withdrawn from consideration pursuant to a restriction requirement. Claims 39 and 41 are objected to for depending from rejected claims.

Claims 31-33, 36-38, 40, 45 and 48-50 are currently being appealed.

IV. Status of Amendments

The appellant filed an amendment April 10, 2006. In the Advisory Action dated May 2, 2006, the Examiner indicated that the amendment was entered.

V. Summary of Claimed Subject Matter

Appellant's invention relates to agonist antibodies that specifically bind the extracellular domain of the human G-CSF receptor to stimulate cell proliferation and differentiation. The agonist antibodies are capable of dimerizing the receptor or

Application No. 10/071,962
 Appeal Brief
 Customer Number 26839
 Attorney Docket No.: TNX98-03-01
 Page 2 of 11

activating phosphorylation of kinases upon binding. In addition, the agonist antibodies of the present invention stimulate proliferation and differentiation of neutrophils and their progenitor cells. This invention is stated at page 4, lines 21-29, of the specification in the Summary of the Invention. FIG.5A and B show the proliferation of human G-CSF receptor transfected mouse cells stimulated by various mouse monoclonal agonist antibodies, including mAb163-93 and mAb174-74-11, as measured by an MTT assay, illustrating the assay used in identifying agonist antibodies of the present invention.

VI. Grounds for Rejection to be Reviewed on Appeal

A. Claims 31-33, 36-38, 40, 45 and 48-50 have been rejected as anticipated by Cunningham et al. (U.S. Pat. No. 5,506,107).

B. Claims 31-38, 40 and 45 have been rejected as anticipated by Adams et al. (U.S. Pat. No. 6,342,220).

VII. Arguments in Support of Patentability Over the 35 U.S.C. §103(a) Rejection

A. Claims 31-33, 36-38, 40, 45 and 48-50 have been rejected as anticipated by Cunningham et al. (U.S. Pat. No. 5,506,107).

1. The Office's Statements in support of Rejection

In the Final Office Action dated January 9, 2006, the Office asserted that:

Cunningham et al. disclose the production of agonist antibodies which are capable of stimulating receptors for various ligands. Production of agonists which stimulate the G-CSF receptor is specifically mentioned at column 12 line 56. At columns 23-24, Cunningham et al. discuss agonist antibodies to the growth hormone receptor, and state that such antibodies may be raised by immunizing animals against growth hormone (and presumably screening the resultant antibodies for agonist properties). Also at columns 23-24, Cunningham et al. disclose such antibodies to be monoclonal, chimeric, or CDR grafted, and compositions comprising such

2. Appellant's Argument that Cunningham Is Non-Enabling Prior Art

Before a reference can even be considered to constitute legally cognizable prior art, it must teach how to make what it discloses. *In re Hoeksema*, 399 F.2d 269, 274, 158 U.S.P.Q. 596, 600-01 (C.C.P.A. 1968) held that the "true test of any prior art relied

Application No. 10/071,962
 Appeal Brief
 Customer Number 26839
 Attorney Docket No.: TNX98-03-01
 Page 3 of 11

on to show or suggest that a chemical compound is old, is whether the prior art is such as to place the disclosed 'compound' in the *possession of the public*" (emphasis added).

Cunnigham does not disclose any agonist antibodies to G-CSF-R. In the parent application U.S. Appl. No. 09/303,155, in an Office Action dated January 9, 2001, the present Examiner admitted that the Cunnigham reference did not disclose any anti-GCSF agonist antibodies. The mere disclosure of the desire to make an agonist antibody to G-CSF is not enabling, and no one prior to the present inventors had made such an antibody. No reference was cited by the Examiner disclosing actual agonist antibodies to G-CSF.

Appellants noted in the argument presented in the Response filed June 29, 2005, that it is easy to obtain a neutralizing antibody because one merely blocks binding of the ligand, i.e. the G-CSF protein, to the receptor. However, an agonist antibody is much more difficult to obtain because it must bind to the receptor in a proper conformation, dimerizing the two (or more) subunits of the receptor and triggering the activation of the receptor in the same manner as the native ligand. In the paper submitted by Appellants by Schneider et al. Blood 59(2):473-480 (1997) (See Exhibit IX), the authors highlight the difficulty in making dimerizing agonist antibodies and pose the question "Why are agonist antibodies to EPO-R so rare?". In that paper, they stated all of their monoclonal antibodies specific for the extracellular domain of EPO receptor should have dimerized the receptor, but in fact only one in the 48 isolated antibodies did so. They also point out that EPO-R is part of a cytokine receptor superfamily, which includes receptors for IL-2, growth hormone, G-CSF, GM-CSF, as well as others. Appellants argued that given the difficulty of making EPO-R agonist antibodies and the similarity between EPO-R and G-CSF-R, a similar situation is true for G-CSF, that agonist antibodies that dimerize and activate the G-CSF-R would be difficult to make and more difficult to identify.

Indeed this proved to be the case in the present invention. In a declaration made by the First Inventor Baufo Ni, in the parent application 09/303,155, stated:

"[M]y coworkers and I screened approximately 500,000 candidates in order to obtain 10 potential agonist antibodies. This required high-throughput screening, with a success ratio of only 1 in 50,000. Measuring ³H-thymidine incorporation at this level would not have

Application No. 10/071,962
 Appeal Brief
 Customer Number 26839
 Attorney Docket No.: TNX98-03-01
 Page 4 of 11

been practical from either a cost standpoint or from the risk of radioactive contamination. We also found that using the D4 cell line expressing an artificial G-CSF receptor, similar in nature to that used by Cunningham, was not sufficiently predictive of a true agonist. As seen in Figure 5B of our application, MA174-12 (solid triangles) appears to be an agonist antibody based on the amount of uptake of MTT as compared to the native G-CSF (solid squares). However, when this same antibody was tested in a colony-formation assay using human bone marrow cells (an assay that more closely mimics a true environment of cells with native human G-CSF receptor) it showed no agonist activity. This clearly shows that there is a substantial difference between an artificial cell-line expressing a recombinant receptor and cells with an endogenous receptor.

Moreover, receptor orientation and disposition has been found to be important to receptor function. Receptor function that is as close to the endogenous form is essential in identifying a true receptor agonist. Because our artificial cell line having a recombinantly expressed G-CSF receptor was not sufficiently predictive of true agonist activity, it is highly unlikely that the hybrid receptor used by Cunningham having an extracellular domain of one receptor type fused to the intracellular domain of another receptor type could sufficiently mimic true receptor function in order to isolate a functional agonist for G-CSF receptor.

Other researchers in the field support the conclusion that an artificial cell-based assay system measuring ³H-thymidine incorporation is too unpredictable to be used to identify agonists for a cytokine receptor in this family. I draw the Examiner's attention to the reference Schneider et al. (Exhibit B). These authors observed that MoAb34 appeared to be agonistic in an assay measuring ³H-thymidine incorporation using artificial cell lines (figure 3B), but in the colony formation assay using human CD34⁺ cells reported in Table 2, this MoAb showed essentially no agonist activity.

Appellants submitted that the assay taught by Cunningham would not lead one to isolate a valid agonist antibody, hence failing to teach "how to make" and thus would not have resulted in putting the public in possession of the invention by merely disclosing the desire to make such an antibody.

Thus, due to the rarity of agonist antibodies to EPO-R which is a member of the same family of receptors as G-CSF, the lack of an adequate assay for detecting agonist antibodies to G-CSF-R, and the lack of any evidence that an agonist antibody to G-CSF-R was made prior to the present invention, makes the Cunningham reference inadequate prior art, lacking enablement. Moreover, as evidenced by the declaration of the Inventor B. Ni, identifying agonist antibodies to G-CSF-R was even more infrequent than EPO-R (i.e., 1:50,000 vs. 1:48). Thus, the public was not in possession of a G-CSF-R agonist antibody prior to the filing of the present application and therefore, the

Application No. 10/071,962
Appeal Brief
Customer Number 26839
Attorney Docket No.: TNX98-03-01
Page 5 of 11

Cuningham reference cannot and does not anticipate the currently claimed invention.

In view of the fact that Cunningham is not valid prior art, the Examiner made a clear error in rejecting the claims as anticipated, and Appellants request that the rejection be reversed.

3. Appellant's Argument that Cunningham does not anticipate Claim 49

Claim 49 is directed to the specific CDR sequences of agonist antibodies mAb166-93 and mAb174-24-11 and their functional variants. The Examiner offered no sequence comparison and indeed there are no sequences disclosed in the Cunningham reference. Therefore, the rejection of claim 49 as anticipated by a reference with no sequences is clearly erroneous and should be reversed.

B. Claims 31-38, 40 and 45 have been rejected as anticipated by Adams et al. (U.S. Pat. No. 6,342,220).

1. The Office's Statements in support of Rejection

In the Final Office Action dated January 9, 2006, the Office asserted that:

Adams et al. disclose the production of agonist antibodies which are capable of stimulating receptors for various ligands. Production of agonists which stimulate the G-CSF receptor is specifically mentioned at column 12 line 56. Fragment and single chain antibodies are discussed at column 18. Methods of making the antibodies are disclosed at column 25. Thus, Adams discloses the desirability of obtaining agonists of the G-CSF receptor, and further discloses methods of obtaining agonist antibodies consistent with the claims. Accordingly, Adams et al. fairly place the claimed invention in the hands of the public.

2. Appellant's Argument that Adams does not anticipate is Non-Enabling Prior Art

Adams et al. does not disclose making or any examples of G-CSF agonist

Application No. 10/071,962
 Appeal Brief
 Customer Number 26839
 Attorney Docket No.: TNX98-03-01
 Page 6 of 11

antibodies. The only disclosure at column 12 is a definition of cytokines and a list of examples. There is no disclosure of making agonist antibodies to G-CSF. Column 12, line 56 states:

“Cytokine ‘superfamily receptors’ and ‘hematopoietic
 55 growth factor superfamily receptors’ are used interchange-
 ably herein and are a group of closely related glycoprotein
 cell surface receptors that share considerable homology
 including frequently a WSXWS domain and are generally
 classified as members of the cytokine receptor superfamily
 60 (see e.g. Nicola et al., *Cell*, 67:1–4 (1991) and Skoda, R. C.
 et al. *EMBO J.* 12:2645–2653 (1993)) Generally, these
 receptors are interleukins (IL) or colony-stimulating factors
 (CSF). Members of the superfamily include, but are not
 limited to, receptors for: IL-2 (b and g chains) (Hatakeyama
 65 et al., *Science*, 244:551–556 (1989); Takeshita et al.,
Science, 257:379–382 (1991)), IL-3 (Itoh et al., *Science*,
 247:324–328 (1990); Gorman et al., *Proc. Natl. Acad. Sci.*

The list continuing on to the next col. 13, at line 13, does disclose G-CSF-R as a member of this family, but this definition does not state “agonist antibodies to” members of this family. The only other reference that the undersigned found was at column 24, line 53, and column 38, line 22, referring to the treatment of a mammal with an antibody in combination with a cytokine, e.g., G-CSF, but no reference to making agonist antibodies to the receptor G-CSF-R. This reference only discloses the making of agonist antibodies to thrombopoietin (o-mpl). Therefore, this reference does not anticipate the claimed invention.

3. Appellant's Argument that Adams is Non-Enabling Prior Art

Even if one interpreted the disclosure at column 12 as disclosing a desire to make agonist antibodies to G-CSF-R, the Adams reference fails to teach “how to make” agonist antibodies to G-CSF-R, and thus would not have resulted in putting the public in

Application No. 10/071,962
Appeal Brief
Customer Number 26839
Attorney Docket No.: TNX98-03-01
Page 7 of 11


possession of the invention by merely disclosing the agonist antibodies to thrombopoetin (c-mpl). For all of the reasons stated in Section A above, Adams is not valid prior art and does not put the public in possession of the claimed invention.

In view of the fact that Adams does not anticipate the claimed invention for failing to disclose agonist antibodies to G-CSF, and Adams is not valid prior art, the Examiner made a clear error in rejecting the claims as anticipated, and Appellants request that the rejection be reversed.

C. Summary

For the foregoing reasons, Appellant believes that the Office's rejection of claims Claims 31-33, 36-38, 40, 45 and 48-50 were erroneous, and reversal of these rejections is respectfully requested.

Respectfully Submitted

By: 
Cheryl A. Liljestrand
Reg. No. 45,275

Dated: October 10, 2006.

Application No. 10/071,962
Appeal Brief
Customer Number 26839
Attorney Docket No.: TNX98-03-01
Page 8 of 11

VIII. Claims Appendix

Claims on Appeal:

31. An agonist antibody, or a binding fragment thereof, that specifically binds to or interacts with the extracellular domain of human G-CSF receptor to stimulate cell proliferation and differentiation.
32. The agonist antibody, or binding fragment thereof, of claim 31, which dimerizes the receptor or activates phosphorylation of kinases associated with the receptor to stimulate cell proliferation and differentiation.
33. The agonist antibody or binding fragment of claim 31 or 32, which stimulates proliferation and differentiation of neutrophils or their progenitor cells.
34. The agonist antibody or binding fragment of claim 31 or 32, wherein the antibody interacts at an epitope between amino acid residues 1-603 (SEQ ID NO:27) of the G-CSF receptor.
35. The agonist antibody or binding fragment of claim 31 or 32, wherein said antibody is a monoclonal antibody.
36. The agonist antibody or binding fragment of claim 31 or 32, wherein the fragment is F(ab')₂.
40. A cell line that produces the agonist antibody or binding fragment of claim 31.
45. A composition comprising at least one agonist antibody according to claim 31 or 32, and a physiologically acceptable carrier, diluent, and/or excipient.
48. An agonist antibody, or binding fragment thereof, that specifically binds to or interacts with the extracellular domain of human G-CSF receptor wherein the

Application No. 10/071,962

Appeal Brief

Customer Number 26839

Attorney Docket No.: TNX98-03-01

Page 9 of 11

human G-CSF receptor used to generate said antibody is a native human G-CSF receptor or a mutant thereof comprising substitutions, insertions, or deletions.

49. The agonist antibody of claim 31, wherein the antibody comprises
SEQ ID NO: 15 to SEQ ID NO 20, or a functional variant of any one of SEQ ID
Nos 15 to 20.
50. The agonist antibody of claim 48, wherein the framework is human or
humanized.

Application No. 10/071,962

Appeal Brief

Customer Number 26839

Attorney Docket No.: TNX98-03-01

Page 10 of 11

IX. Evidence Appendix

The attached evidence includes the reference Schneider et al. submitted previously with the June 29, 2005 Response.

Homodimerization of Erythropoietin Receptor by a Bivalent Monoclonal Antibody Triggers Cell Proliferation and Differentiation of Erythroid Precursors

By Helmut Schneider, Warak Chaovapong, David J. Matthews, Cyrus Kerkar, Robert T. Cass, Hongjun Zhan, Mark Boyle, Tony Lorenzini, Steve G. Elliott, and Lutz B. Gibbel

Erythropoietin (EPO) stimulates proliferation and differentiation of erythroid progenitor cells. Several lines of evidence indicate that the most likely mechanism of EPO receptor (EPO-R) activation by EPO is homodimerization of the receptor on the surface of erythrocyte precursors. Therefore, we argued that it should be possible to raise EPO-R monoclonal antibodies (MoAbs) that would activate the receptor by dimerization and thus mimic EPO action. We have identified such an agonist MoAb (MoAb34) directed against the extracellular EPO binding domain of the EPO-R. This bivalent IgG antibody triggers the proliferation of EPO-dependent cell lines and induces differentiation of erythroid precursors *in vitro*. In contrast, the monovalent Fab fragment, which cannot dimerize the receptor, is completely inactive. The mechanism of receptor activation by homodimerization implies that at high ligand concentrations the formation of 1:1 recep-

tor/ligand complexes is favored over 2:1 complexes, thereby turning the ligand agonist into an antagonist. Thus, EPO and MoAb34 should self-antagonize at high concentrations in both cell proliferation and differentiation assays. Our data indeed demonstrate that EPO and MoAb34 antagonize ligand-dependent cell proliferation with IC_{50} values of approximately 20 and 2 μ M/L, respectively. Erythroid colony formation (BFU-E) is inhibited at MoAb34 concentrations above 1 μ M/L. Furthermore, we analyzed the MoAb34:EPO-R interaction using a mathematic model describing antibody-mediated receptor dimerization. The data for proliferation and differentiation activity were consistent with the receptor dimer formation on the cell surface predicted by the model.

© 1997 by The American Society of Hematology.

ERYTHROPOIETIN (EPO), a 34-kD glycoprotein hormone, is the major regulator of mammalian erythropoiesis.¹ EPO acts on erythroid progenitor cells by preventing apoptosis,^{2,3} stimulating proliferation of erythroid precursor cells, and inducing differentiation into mature erythrocytes. These effects are transduced by the binding of EPO to a specific EPO receptor (EPO-R) on the surface of committed erythroid progenitor cells.⁴ Deletion of EPO and EPO-R genes in mice has shown that EPO is crucial for the survival, proliferation, and differentiation of late committed progenitors (colony-forming unit-erythroid [CFU-E]), but not of early progenitors (burst-forming unit-erythroid [BFU-E]).⁵ Mice homozygous for a deletion of either EPO or EPO-R genes die during embryogenesis due to failure of erythropoiesis in the fetal liver. The EPO-R is a member of the cytokine receptor type I superfamily, which includes the receptors for interleukin-2 (IL-2) through IL-7, granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor (G-CSF), growth hormone (GH), prolactin (PRL), thrombopoietin (TPO), leukemia inhibitory factor, and leptin.⁶⁻⁸

The receptors for EPO, GH, PRL, TPO, and G-CSF appear to be triggered by ligand-induced receptor homodimerization.⁹⁻¹⁴ For the EPO-R, direct evidence for the dimerization model has been provided by the recent discovery of a dimeric peptide that binds to and activates the receptor.¹⁵ The crystal structure of the peptide in complex with the extracellular domain of the EPO-R (EPO binding protein [EPObp]) shows that the peptide dimer binds to two molecules of EPObp.¹⁶ The formation of complexes between EPO and two molecules of EPObp in solution has been described using light-scattering, sedimentation equilibrium, and isothermal titration calorimetry techniques.¹⁷ Stable EPObp₂EPO complexes have also been purified (Zhan H, Kerkar C, Kass R, Savel L, Gibbel LB, manuscript submitted).

Previous evidence for EPO-induced receptor dimerization on the cell surface is based primarily on constitutively active EPO-R mutants, which contain point mutations introducing

cysteine substitutions into the extracellular domain at amino acid positions R129, E132, and E133.¹³⁻¹⁵ The EPO-R mutants form disulfide-linked homodimers in the endoplasmic reticulum and on the cell surface.¹⁴ Based on sequence alignments with the related GH receptor, these mutations are expected to be in the receptor-dimer interface region. Expression of the constitutively active EPO-R (R129C) mutant in BaF3 cells results in factor-independent proliferation, and expression in primary cultures of mouse fetal liver cells induces EPO-independent erythroid differentiation.¹⁷ Furthermore, mice infected with a retrovirus carrying the EPO-R (R129C) mutant develop erythroleukemia.¹⁸ Truncated receptor mutants that lack part of the intracellular signaling domain are dominant-negative for signal transduction when coexpressed with the wild-type EPO-R.^{12,19} Both wild-type and truncated receptors can be coimmunoprecipitated with an antibody directed against the C-terminus of the wild-type receptor, which is not present in the truncated form,¹⁹ further suggesting the presence of receptor dimers on the cell surface.

Receptor dimerization has been analyzed in great detail for the GH receptor.²⁰⁻²¹ GH has two distinct receptor binding sites. At high ligand concentrations, formation of 1:1 complexes via the high-affinity GH site 1 is favored over 2:1 complexes, preventing GH receptor signaling, and Fuh et

From the Department of Receptor Biology, Amgen Pharmaceutical Corp, South San Francisco; and the Angen Center, Amgen, Thousand Oaks, CA.

Submitted May 1, 1996; accepted September 3, 1996.

Address reprint requests to Helmut Schneider, PhD, Amgen Pharmaceutical Corp, 393 Foster Point Blvd, South San Francisco, CA 94080.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1997 by The American Society of Hematology.
0883-4471/97/0002-0000\$05.00/0

also demonstrated self-antagonism of GH in a GH-dependent cell proliferation assay at GH concentrations greater than 100 nmol/L. Homodimerization and signal transduction of GH receptor can also be achieved by specific monoclonal receptor antibodies. IgG-type antibodies are bivalent molecules that bind to two antigen molecules at the same time. IgGs specific to GH receptor therefore are able to dimerize and stimulate the receptor. Like GH, these antibodies are self-antagonists at high concentrations.²³ Similar agonist antibodies have also been described for the PRL receptor.²³

We have raised a monoclonal antibody (MoAb) directed against EPObp, which mimics EPO action by inducing ligand-dependent cell proliferation and differentiation. Self-antagonism of EPO has not been reported so far, probably because the concentrations of EPO tested have not been high enough. We analyzed EPO at concentrations up to 30 μ mol/L and were able to detect specific inhibition of EPO-dependent proliferation. This provides further evidence that EPO triggers its receptor by ligand-induced dimerization.

MATERIALS AND METHODS

Cell lines. BaF3, a murine IL-3-dependent cell line,²⁴ was a gift from Dr H. Lodian (Whitehead Institute, Cambridge, MA). An EPO-dependent BaF3/EPO-R cell line was generated by transfecting the full-length human EPO-R into BaF3 cells. A cDNA encoding the full-length human EPO-R is a gift from Dr J. Winkelmann, University of Cincinnati, OH; nucleotide sequence identical to that used by Winkelmann et al²⁵ and Jones et al²⁶ was cloned into plasmid expression vector pRC/CMV (Invitrogen, San Diego, CA). After electroporation into BaF3 cells, the cells were cultured for 3 days in RPMI 1640 medium containing 10% fetal bovine serum (FBS) and IL-3. Cells were washed twice, transferred into RPMI 1640 medium plus 125 pmol/L EPO, and selected for EPO-dependent growth. Individual clones were selected by limiting-dilution cloning. The EPO-dependent cell line chosen for this study proliferates in the presence of EPO with an EC_{50} of 15 pmol/L. Scatchard analysis showed 800 receptors per cell that bind EPO with 300-pmol/L affinity if, for simplification, single-site binding is assumed (data not shown). Cells were maintained in RPMI 1640 medium with 10% FBS, 20 mmol/L HEPES, pH 7.8, and 10 μ mol/L mercaptoethanol supplemented with 100 pmol/L EPO. BaF3 cells were supplemented with 10% IL-3 containing WEHI-231-conditioned medium.

UT-7/EPO cells²⁷ were a gift from Dr Norio Kanamaru, and were grown in 1X Iscove's modified Dulbecco's medium (IMDM) with L-glutamine, 25 mmol/L HEPES, 3.023 g/L uridine bicarbonate, 10% FBS, and 1% L-glutamine-penicillin-streptomycin solution (Invitrogen Scientific, Santa Ana, CA) containing 270 pmol/L EPO.

Expression and affinity purification of soluble human EPO-R. DNA encoding a soluble (truncated) EPO-R (EPObp) was generated by polymerase chain reaction (PCR) using the full-length cDNA as template. The amplification product introduces a TAG termination codon 5' of the transmembrane region and encodes the extracellular domain consisting of amino acids 1 through 249 of the published sequence.²⁸ The PCR product was subcloned into expression vector pRC/CMV (Invitrogen) and stably transfected into CHO cells. Individual clones secreting EPObp were selected by limiting-dilution cloning. Roller bottles (surface area, 1,710 cm²; Corning, Corning, NY) were seeded with the stable cell line, which was then grown to confluence in RPMI 1640 medium plus 10% FBS. The cells were washed twice in serum-free RPMI 1640 medium and cultured in 200 mL serum-free RPMI 1640 medium. Cell supernatant was collected after 2 days, and fresh medium was added for another 2 days.

EPO was oxidized with 10 mmol/L NaIO₃ and biotinylated using

10 mmol/L biotin hydrazide (Pierce, Rockford, IL) following the manufacturer's instructions. A ligand affinity column was prepared by immobilizing biotinylated EPO (10 ng) on Streptavidin 3M Empress beads (3 mL; Pierce) overnight in Dulbecco's phosphate-buffered saline (PBS) (Invitrogen Scientific) at 4°C. The beads were separated from the supernatant by centrifugation, and incubated with 10 mmol/L biotin in PBS for 2 hours at 4°C to saturate all biotin binding sites. After washing with PBS, the EPO-treated beads were packed in a glass column (Omniject Attach Corp., Deerfield, IL). Cell supernatant (10 L) was concentrated and dialyzed to 1 L in 20 mmol/L Tris hydrochloride, pH 7.6, and loaded on the column at a flow rate of 0.7 mL/min. The column was washed with 50 mL 20 mmol/L Tris hydrochloride, pH 7.6. Bound EPObp was eluted with 750 mmol/L NaCl in 20 mmol/L Tris hydrochloride, pH 7.6. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis showed a single 30-kD EPObp band. The EPObp fractions were pooled and concentrated, and the buffer was exchanged with PBS to a final concentration of 0.8 mg/mL.

Generation and screening of MoAbs. Five Balb/c mice were immunized by seven subcutaneous injections at two sites over a period of 14 weeks. Each 50- μ L injection contained 25 μ g EPObp in Freund's adjuvant. After 12 weeks, all mice had developed anti-EPObp antibody titers. The dilutions needed to reach a half-maximal signal in an enzyme-linked immunosorbent assay (ELISA) ranged from 1:20,000 to 1:50,000. An additional final injection of 150 μ g EPObp was administered intravenously to the mouse expressing the highest antibody titer. After 3 days, spleen cells were isolated and fused with myeloma strain P3X63Ag8.653 (American Type Culture Collection, Rockville, MD; CRL 1580). After selection in hypoxanthine-thymine-aminopterin-thymidine medium (Sigma, St. Louis, MO) for 10 days, a total of 475 supernatants were screened for specific antibody production by ELISA. Positive clones were transferred to 24-well microtiter plates, and supernatants were assayed in a thymidine uptake proliferation assay using the cell line BaF3/EPO-R and the parental BaF3 as a control. Hybridoma clones MoAb34 was subcloned twice by limiting dilution. Ig isotyping was performed using the IsoStrip Mouse Monoclonal Antibody Isotyping Kit from Boehringer Mannheim (Indianapolis, IN).

Purification of MoAb34 and Fab preparation. Hybridomas were grown in 47.5% RPMI 1640 medium, 47.5% Dulbecco's modified Eagle's medium, and 5% FBS. Culture supernatant was filtered through a 0.2- μ m membrane. A 6-mL protein G-Sepharose 4 fast-flow column (Pharmacia Biotech, Piscataway, NJ) was packed with 80 psi pressure. A 1-L sample was loaded at 4 mL/min at 4°C, followed by washing with greater than 5 column vol PBS. MoAb34 was then eluted from the column with Immopure IgG elution buffer (Pierce) at 1 mL/min. The eluate was immediately neutralized to pH 7.5 by adding 3 mol/L Tris. The purity was evaluated by nonreducing SDS-PAGE. Fab fragments were generated by papain cleavage using the Immopure IgG1 Fab Preparation Kit (Pierce) following the manufacturer's instructions. The Fab was further purified by gel filtration using a Superdex 75 column (1.6 cm \times 60 cm; Pharmacia), eluted with PBS, and analyzed for purity by SDS-PAGE.

ELISA. Because we expected the number of agonist antibodies to be low, we used two different methods for immobilization of the EPObp to ensure identification of a maximum number of anti-EPObp MoAbs. In ELISA 1, EPObp was covalently immobilized. EPObp was oxidized in 1 mmol/L NaIO₃ and 30 mmol/L sodium borate, pH 7.5, at 4°C for 30 minutes in the dark. The protein was separated from peroxidase on a NAP-5 column (Pharmacia) and incubated on hydrazide-activated microtiter plates (Unifry, San Diego, CA) at 2 μ g/mL (100 μ L per well) for 1 hour at room temperature. Plates were washed and blocked with PBS and 20 mg/mL bovine serum albumin (BSA) for 1 hour. In ELISA 2, Polystyrene microtiter plates

BEST AVAILABLE COPY

EPO RECEPTOR DIMERIZATION

475

(Nune, Roskilde, Denmark) were incubated for 1 hour at 37°C with 10 μ g/mL MoAb 3B12, a specific, nonneutralizing rat MoAb directed against EPObp (B. van Dyke, personal communication, February 1994). The plates were washed and blocked, and then EPObp (1 μ g/mL) was added in ELISA buffer (PBS, 1 mg/mL BSA, and 0.02% Tween-20) for 1 hour at 37°C. After immobilization of EPObp, both ELISA protocols were identical. Antibody-containing samples in ELISA buffer were added and incubated for 1 hour at 37°C. After washing, plates were incubated with a sheep anti-mouse IgG coupled to horseradish peroxidase (HRP) (Sigma) at 0.1 ng/mL in ELISA buffer for 1 hour at 37°C. The plates were then washed, and 100 μ L TMB/H₂O₂ developing solution (Pierce) was added and incubated for 5 minutes. Color development was stopped by adding 100 μ L 1-mol/L sulfuric acid, and the OD_{450nm} was determined using a plate reader (Molecular Devices, Sunnyvale, CA).

Thymidine uptake proliferation assay. BaF3 and BaF3/EPO-R cells were grown to the late logarithmic phase, collected by centrifugation, washed three times with RPMI 1640 media containing 10% FBS and 10 mmol/L HEPES, pH 7, in the absence of EPO and IL-3, and then starved in the same media for 2 hours. Arbitrarily test samples (hybridoma supernatants or purified proteins) were diluted at least fivefold into 100 μ L media, and 100 μ L cells were added (25,000 cells per well). EPO was dialyzed against 10 mmol/L HEPES, pH 7.0, and 100 μ L test samples were combined with 100 μ L cells (25,000 cells per well) in twofold-concentrated medium. Plates were incubated for 4 hours at 37°C and 5% CO₂ in a humidified tissue culture incubator. Then, 0.5 μ Ci methyl-³H-thymidine (Amersham, Arlington Heights, IL; 1 mCi/mL, 20 Ci/mmol) diluted into 20 μ L medium, was added, and the incubation was continued for another 15 hours. Cells were harvested onto glass fiber filters using a Tomtec cell harvester, and incorporated radiolabel was determined using a Microbeta 1430 scintillation counter (Wallac, Turku, Finland).

UT-7/EPO cells were grown to approximately 3×10^5 /mL, collected by centrifugation, washed twice with PBS, and resuspended at 50,000/mL in assay medium (RPMI 1640 medium with 1% L-glutamine and 4% FBS). Tissue culture plates (96-well) were loaded with 100 μ L test samples (diluted at least fivefold in assay medium) and 50 μ L cells per well and incubated at 37°C and 5% CO₂. After 72 hours, 0.5 μ Ci methyl-³H-thymidine diluted in 50 μ L assay medium was added, and the cells were incubated for another 4 hours at 37°C and 5% CO₂. Labeled cells were harvested onto glass fiber filters using a PHD cell harvester (Cambridge Technology, Inc., Watertown, MA). Filters were rinsed with 2-propanol, dried, and counted in a Beckman model LS6000TC scintillation counter (Fullerton, CA).

Cell-based EPO binding-competition assay. OC1M1 cells, a human erythroleukemia cell line that expresses EPO-R on the cell surface,³⁸ were grown in IMDM, 10% FBS, and 1% penicillin-streptomycin to approximately 2×10^5 cells/mL. Cells were collected by centrifugation, washed two times in binding buffer (RPMI 1640 medium, 1% BSA, and 25 mmol/L HEPES, pH 7.3), and resuspended in binding buffer containing 0.1% NaN₃ and 10 μ g/mL cycloheximide B or 1×10^5 cells/mL. Tissue culture plates (96-well) were loaded with 100 μ L cells, 10 μ L sample, and 10 μ L [¹²⁵I]-EPO (Amersham, high specific activity, 3,000 Ci/mmol, 2 mCi/mL) and incubated for 3 hours at 37°C in a humidified tissue culture incubator. Then, the cells were centrifuged through phthalate oil (60:40 vol/vol diethyl/monyl phthalate) in filter tubes. The tubes containing cell pellets were quick-frozen in a dry ice-ethanol bath, and the cell pellet was clipped and then counted in a Pharmacia-LKB (Uppsala, Sweden) 1277 GammaCounter automatic gamma counter.

BFUe cell differentiation assay. Normal human donors underwent lymphopheresis according to standard protocols to purify CD34⁺ erythroid cells.³⁹ Human blood was obtained after informed

consent. The cells were washed, resuspended in Hanks balanced salt solution (HBSS), and separated by density centrifugation over a gradient (Ficoll-Paque; Pharmacia Biotech). The low-density cells were collected, washed with HBSS, and resuspended in PBS supplemented with 0.5% BSA and 5 mmol/L EDTA at a concentration of 5×10^5 cells/mL. From these cells, purified CD34⁺ cells were obtained using a CD34 Progenitor Cell Isolation Kit (QSep/10; Miltenyl Biotech GmbH, Bergsch Gladbach, Germany).

The *in vitro* BFU-E assay on purified CD34⁺ cells was performed in methylcellulose. The medium contained 20% FBS, 0.33% IMDM (GIBCO, Grand Island, NY), 3-mercaptoethanol, nucleosides, cholesterol, sodium pyruvate, Hu-transferrin, lipids, Hu-inulin, deionized BSA, and 100 ng/mL stem cell factor (SCF).⁴⁰ A suspension of CD34⁺ cells (10,000/mL), 0.015 mL SCF (20 μ g/mL), and a combination of sample and medium totaling 3 mL was prepared in sterile polystyrene tubes. Duplicate 1-mL aliquots were placed into 35 \times 100-mm tissue culture plates. The plates were incubated at 37°C and 10% CO₂ in a humidified tissue culture incubator. Erythroid colonies (orange to red in color) were scored after 14 to 20 days.

BIAcore analysis. Kinetic parameters for the interaction of MoAb34 and its Fab fragment (Fab34) with EPObp were measured using real-time biospecific interaction analysis (BIAcore).⁴¹ The BIAcore system, CM-5 sensor chip, and reagents were from Pharmacia Biotech (Piscataway, NJ). All injections on the sensor chip surface were at a flow rate of 5 mL/min and 25°C unless otherwise noted. Between injections of reagents, the sensor chip was continuously washed with 10 mmol/L HEPES, pH 7.2, 150 mmol/L NaCl, 3.4 mmol/L EDTA, and 0.005% surfactant P₂₀. The interaction of MoAb34 with EPObp was characterized by coupling approximately 6,800 resonance units (RU) of MoAb34 to the sensor chip surface using standard amine immobilization chemistry.⁴² EPObp samples of 10 to 1,500 nmol/L were injected for 7 minutes over the MoAb34 surface and over a control flow cell. After each injection of EPObp, a 1-minute pulse of 1 mmol/L formic acid was used to regenerate the MoAb34 surface. To measure the association of EPObp and Fab34, oxidized EPObp (~500 RU) was immobilized via carbonyl-drug coupling to the carbonylmethylated dextran matrix.⁴³ Injections of Fab34 spanned a concentration range of 1 to 500 nmol/L. After each injection of Fab34, the EPObp surface was regenerated with a 50- μ L pulse, at 50 μ L/min, of 10 mmol/L 3-(cyclohexylamino)-1-propanesulfonic acid (CAPS; pH 8.4). Association and dissociation rate constants were determined by least-squares fitting using BIAevaluation software (Pharmacia Biotech). To minimize potential rebinding effects, only the initial 15 seconds of each dissociation profile was used for calculation of the dissociation rate constant.

RESULTS

MoAb34 stimulates proliferation of BaF3/EPO-R cells. We have isolated a total of 48 MoAbs specific for EPObp.




Fig 1. MoAb34 immunoblot analysis of EPObp. EPObp was heat-denatured and analyzed by reducing SDS-PAGE on a 15% acrylamide gel and subsequent transfer to nitrocellulose. The blot was incubated with MoAb34 (10 μ g/mL) and subsequently with anti-mouse IgG coupled to horseradish peroxidase.

BEST AVAILABLE COPY




Fig 2. BIAcore analysis of MoAb34. Sensorgrams of various concentrations of EPObp (10 to 1,500 nmol/L) injected over immobilized MoAb34, corrected by subtraction of data from control surfaces. The ligand was removed after 430 seconds, and dissociation was measured after this point. Data from 8 representative free-EPObp concentrations (nmol/L) from a total of 16 are shown: 1,500 (a), 798 (b), 199 (c), 100 (d), 75 (e), 60 (f), 25 (g), and 10 (h).

the soluble extracellular ligand-binding domain of the human EPO-R. The hybridoma supernatant of MoAb clone 34 stimulated thymidine uptake in BuF3/EPO-R cells, but did not stimulate proliferation in parental BuF3 cells. MoAb34 is an IgG MoAb that was subtyped as IgG₁. Immunoblot analysis of heat-denatured and reduced EPObp suggested that MoAb34 recognizes a linear epitope (Fig 1). MoAb34 did not compete with [¹²⁵I]-EPO in a binding-competition assay using human OCIM1 cells²⁴ (data not shown). Thus, MoAb34 does not interfere with the binding of EPO to its receptor, indicating that there is no overlap of MoAb34 and EPO binding epitopes on the receptor. The binding kinetics of both MoAb34 and Fab34 to EPObp were characterized using surface plasmon resonance (Fig 2). For MoAb34 kinetics, the antibody was immobilized to avoid avidity effects. For Fab34 kinetics, we immobilized EPObp. The kinetic constants for MoAb34 and Fab34 are summarized in Table 1.

MoAb34, but not the Fab fragments, stimulate proliferation in EPO-dependent cells. Purified MoAb34 was able to stimulate proliferation in EPO-dependent cell lines. A dose-dependent response evaluation in a [³H]thymidine uptake cell proliferation assay showed EC₅₀ values of approximately 10 nmol/L (Fig 3A) in BuF3/EPO-R cells. The effect of MoAb34 was specific to EPO-R, because it did not stimulate growth of the parental BuF3 cell line (data not shown). Under identical conditions, the maximal amount of [³H]thymidine incorporation caused by EPO (Fig 4) was eight-fold to 10-fold higher than the incorporation caused by MoAb34 (Fig 3A). In contrast to the bivalent MoAb34, monovalent Fab fragments did not stimulate proliferation of the BuF3/EPO-R cell line (Fig 3A), even though the

affinities of MoAb34 and Fab34 to EPObp were similar (Table 1). MoAb34 was even more active in the cell line UT-7/EPO,²⁷ which expresses endogenous EPO-R, where it stimulated proliferation with an EC₅₀ of approximately 300 pmol/L (Fig 3B). The maximum incorporation was close to the value obtained with EPO. This may be due to the higher concentration of EPO-R molecules on the surface of UT-7/EPO cells, which contain 2,400 receptors per cell,^{27,28} versus 800 for BuF3/EPO-R (data not shown). For higher receptor concentrations, the ligand concentration necessary to induce dimerization of the receptor should be lower. At higher concentrations (>200 nmol/L), MoAb34 antagonizes cell proliferation in both cell lines (Fig 3), as expected based on the homodimerization model. The resulting dose-dependent proliferation curves have a bell-shaped character with IC₅₀ values for self-antagonism of approximately 2 μ mol/L.

If EPO homodimerizes the receptor, then self-antagonism should also be observed at high EPO concentrations. We demonstrated this using our BuF3/EPO-R cell proliferation assay (Fig 4). Proliferation significantly decreased above 3 μ mol/L; however, complete inhibition was not observed at the concentrations tested. The estimated IC₅₀ value was approximately 20 μ mol/L, representing 74,000 U/mL or 370 μ g/mL of EPO. This is an extremely high concentration—BuF3/EPO-R cells proliferate with an EC₅₀ of 15 pmol/L, which is six orders of magnitude lower. To confirm that the decrease in signal in BuF3/EPO-R cells was specific to EPO and not due to toxicity or other artifacts at such high ligand concentrations, parental BuF3 cells were incubated with EPO at identical concentrations in the presence of IL-3. No decrease in IL-3-dependent

BEST AVAILABLE COPY

Table 1. Surface Analysis of MoAb34 and Fab34 Interactions With EPObp

Immoblized Molecule	Analysis	K_D (mM, 1×10^3)	K_D (nM)	K_D (nmol/L)
MoAb34	EPObp	3.1×10^3	0.038	84
EPObp	Fab34	4.2×10^3	0.025	53

Determinations of affinity were made from kinetic measurements of K_D and k_{off} , and K_D was inferred from the relationship $K_D = k_{off}/k_{on}$. Standard errors in all cases were <10%.

proliferation was observed at any EPO concentration (Fig 4).

MoAb34 induces differentiation of CD34⁺ erythroid progenitor cells in the presence of SCF. The differentiation




Fig 3. Dose-dependent proliferation of EPO-sensitive cells by MoAb34. (A) Proliferation of BaF3/EPO-R cells in the presence of [³H]-thymidine and various concentrations of MoAb34 (□) and Fab34 (○). (B) Proliferation of UT-7/EPO in the presence of [³H]-thymidine and various concentrations of MoAb34 (□), control (anti-Asi) antibody (●), and EPO (Δ), respectively. Experiments were made in duplicate; the mean values are shown.




Fig 4. Effect of high EPO concentrations on the proliferation of BaF3/EPO-R cells (○) and parental BaF3 cells (Δ). Both cell lines were assayed with identical dilution series of EPO. BaF3 cells were supplemented with 10% WEHI-conditioned media as a source for IL-3. Experiments were made in duplicate; the mean values are shown.



of BFUe cells in the CD34⁺ population to erythroid burst is dependent on EPO and SCF. MoAb34 was able to induce in vitro differentiation of human CD34⁺ erythroid cell precursors. In two independent experiments, duplicate sets of CD34⁺ cells were treated with various concentrations of MoAb34, EPO, or a control antibody. The cells were incubated in the presence of a fixed concentration of SCF (100 ng/mL). After 19 days in the first experiment and 20 days in the second experiment, colonies from BFUe cells were visible in the presence of either MoAb34 or EPO, but not in the antibody control (Table 2). The colonies showed typical red color and could be identified as erythroid cells by microscopic analysis (Fig 5). As in the cell proliferation assays described earlier, EPO was more potent than MoAb34. Colonies developed at the lowest EPO concentration tested (1.3 pmol/L), whereas no erythroid colonies were observed at a MoAb34 concentration less than 7 nmol/L. Both the absolute number of colonies and the size of the colonies were higher in the presence of EPO than in the presence of MoAb34. The approximate EC_{50} value was 13 nmol/L, and the highest stimulation of differentiation by MoAb34 observed was 22 to 230 nmol/L, similar to the maxima observed in the cell proliferation assays (Table 2). In addition, at concentrations above 720 nmol/L, MoAb34 self-agonizes in this cell differentiation assay. All these data demonstrate that both cell proliferation and differentiation are driven by ligand-induced receptor homodimerization.

Agonist activity of MoAb34 correlates well with a model for antibody-mediated receptor dimerization. Mathematical models have been developed to describe the formation of receptor dimers on the cell surface by bivalent ligand antibodies¹⁵ or by OH.¹⁶ We investigated how the agonist activity of MoAb34 would correlate with the occurrence of receptor dimers predicted by the model of Perelson.¹⁵

Briefly, Perelson postulates a two-step mechanism, whereby the formation of 1:1 complexes is driven by the

BEST AVAILABLE COPY

affinity constant $K_A (= 1/K_D)$. Subsequent dimer formation is dependent on a "cross-linking" constant K_X , which includes K_A but also depends on the effective concentration of receptors on the cell surface and other factors. In the following equations, "Ab" stands for antireceptor antibody and "R" for receptor:



The concentration of dimer is calculated as

$$[dimer] = \frac{[R_{total}]}{2} \left\{ 1 + \frac{1}{2\delta} (1 - \sqrt{1 + 4\delta}) \right\},$$

$$\text{where } \delta = \frac{[Ab][R_{total}]K_AK_X}{(1 + 2K_A[Ab])}$$

assuming that the amount of antibody bound is small compared with the total antibody concentration. The maximal concentration of dimer is solely dependent on K_A :

$$[dimer]_{max} = \frac{1}{2K_A} = \frac{1}{2} K_D$$

If the percentage of receptor/antibody 2:1 complexes versus the total number of receptors is plotted against the antibody concentration, a symmetric bell-shaped curve is predicted. The maximum of 2:1 complexes occurs at a defined antibody concentration equal to half the antibody K_D value. Details of the above derivation may be found elsewhere.³

Figure 6 fits the data of the MoAb34 cell proliferation and differentiation assays to the equation. The resulting bell-shaped curves for the proliferation assays correlate well with the assay data. The obtained 2:1 complex maxima were 114 nmo/L for BaF3/EPO-R cells and 26 nmo/L for UT-7/EPO cells. According to the model, this translates to apparent K_D values of 228 and 52 nmo/L, respectively. In good agreement with the K_D value of 84 nmo/L determined by BIAcore analysis (Table 1). These results demonstrate that the agonist activity of the bivalent MoAb34 in cell proliferation and differentiation assays is consistent with ligand-induced homodimerization of the EPO-R on the cell surface.

DISCUSSION

Homodimerization of the EPO-R by EPO on the cell surface is believed to be the key event in signal transduction.⁴ The model for homodimerization of the EPO-R by EPO implies that it should be possible to trigger the receptor by

Table 2. BFCs in Vitro Differentiation Assay

Factor	Experiment 1 (19 d)		Experiment 2 (30 d)	
	Concentration (nmo/L)	No. of Colonies (duplicates)	Concentration (nmo/L)	No. of Colonies (duplicates)
EPO	0.0026	30/22	0.0013	6/11
	0.0056	31/27	0.0036	21/27
	0.0130	48/56	0.0084	48/52
	0.0258	68/61	0.0130	81/87
	0.0516	73/63	0.0258	142/100
			0.180	133/120
MoAb34	3.6	0/0	1.8	0/0
	7.2	0/2	3.6	0/0
			7.2	0/0
			14.4	2/5
	21.6	12/10	21.6	10/7
	38.0	16/3	38.0	13/12
	72.0	10/7	72.0	7/15
			144	5/14
	216	11/4	216	4/13
	360	4/3	360	6/9
MoAb control	720	2/6	720	0/2
	1,080	0/1	1,080	0/0
	1,800	0/1		
			6.8	0/0
	34.4	0/0	34.4	0/0
	206	0/0	206	0/0
	344	0/0		
			688	0/0

Purified CD34⁺ cells (10,000 cells per duplicate sample) were incubated in methylcellulose in the presence of the indicated sample at different concentrations. Erythroid colonies were counted after 19 days (experiment 1) or 30 days (experiment 2), respectively. For each experiment, the number of colonies of both duplicates are given.

BEST AVAILABLE COPY

EPO RECEPTOR DIMERIZATION

479



Fig 5. BFUe colonies stimulated by MoAb34 and EPO. Purified CD34⁺ cells from human peripheral blood were incubated for 20 days. BFUe colonies were identified by microscopic examination and photographed. Representative colonies obtained at 2 different concentrations of EPO and MoAb34, respectively, are shown. (A) 146 nmol/L MoAb34; (B) 36 nmol/L MoAb34; (C) 130 pmol/L EPO; (D) 6.8 pmol/L EPO.

bivalent MoAbs directed against EPObp. For the related GH receptor, a variety of agonist MoAbs have been reported.²³ MoAb34 is such a bivalent IgG with the ability to dimerize two receptor molecules. We have shown stimulation of cell proliferation in BaF3/EPO-R and UT-7/EPO, as well as stimulation of cell differentiation in CD34⁺. On the other hand, monovalent Fab fragments, which cannot form receptor dimers, are totally unable to stimulate cell proliferation in BaF3/EPO-R, although their affinity for EPObp is similar. In all three test systems used, we observed self-antagonism of MoAb34 at high concentrations. This is precisely what the homodimerization mechanism requires: when high ligand concentrations drive the equilibrium from 2:1 complexes toward 1:1 complexes, there are fewer receptor dimers on the cell surface triggering signal transduction. Self-antagonism has been described for agonist GH receptor and PRL receptor antibodies, too,^{22,24} suggesting that all three receptors are activated by the same principle.

Over the full antibody concentration range, activation of

cell proliferation and differentiation shows a bell-shaped response curve. The maximum observed in all three *in vitro* experiments occurs at similar MoAb34 concentrations, in close vicinity to its K_d . Indeed, a mathematic model²⁵ predicts that a maximum of 2:1 receptor/antibody complexes is formed at a concentration of $0.5 \times K_d$. We were able to fit the data obtained in the cell proliferation and differentiation assays to this model. The correlation of agonist activity with the predicted occurrence of 2:1 complexes further supports the homodimerization model. In contrast, data reported for agonist antibodies stimulating the GH and PRL receptor show a maximum response in proliferation assays at concentrations approximately two orders of magnitude higher than their K_d values.^{22,23} It is possible that the affinities of anti-PRL receptor antibodies were overestimated due to avidity effects, since they were determined by binding analysis of radiolabeled antibodies to whole-cell homogenates.²⁷ In the GH-GH receptor complex, there is a substantial contact surface between the two GH receptor molecules in addition to

BEST AVAILABLE COPY




Fig 4. Fit of data obtained from *in vitro* cell assays to a mathematical model describing antibody-mediated receptor dimerization. Determination of K_D by Biacore analysis showed a value of $\sim 80 \text{ nM}$. Baseline values for proliferation (^{3}H -thymidine incorporation) in the absence of MoAb34 were subtracted. (A) Proliferation of BaF3/EPO-R cells; (B) proliferation of UT-7/EPO cells; (C) differentiation of CFU-E cells. The mean number of colonies obtained in the 2 columns of experiment 3 (Table 2) was used.

the hormone-receptor interface, which contributes to the binding energy.¹¹ In contrast, receptor-receptor interaction in the EPObp:EPO complex seems to be poor. If there is any.¹¹

We have demonstrated for the first time that EPO exhibits self-antagonism (Fig 4). The concentration of EPO needed was more than four orders of magnitude higher than that necessary for a maximal response. The likely reason that this effect has not been reported previously is that the micromolar concentrations necessary have not been tested in proliferation assays. The IC_{50} for EPO self-antagonism is approximately 10-fold higher than the IC_{50} for human GH self-antagonism, whereas EC_{50} values for agonism of EPO and GH are similar.²² There are several explanations possible. The IC_{50} of EPO self-antagonism could be higher due to a

lower affinity of site 1 for EPO than for GH. Alternatively, different receptor densities and site 2 affinities could account for the observed discrepancies. Unfortunately, the available data are limited. A well-derived K_D is available for GH ($K_D = 0.3 \text{ nM}$),²³ but the corresponding site of EPO has not been as well characterized ($K_D \sim 0.5 \text{ nM}$).¹¹ On the other hand, the K_D of site 2 has been well determined for EPO (0.85 to $1.35 \text{ } \mu\text{M}$),¹¹ but it is unknown for GH. Previous study has demonstrated that there are interactions between the extracellular domains of GH receptor²⁴; however, the contributions of the membrane-spanning and intracellular domains to the dimerization of cytokine receptors are poorly understood.

A counterpart to the inactive Fab fragments of MoAb34 would be an EPO mutant that lacks the putative second binding site. Such a mutant would still be able to bind to the receptor, but it would not be able to cause dimerization and therefore should be inactive in a proliferation assay. For GH, Fuh et al²⁵ have shown that a mutant in which residue Gly-120 is replaced by arginine disrupts the site 2 receptor binding site. This mutant binds to GH receptor with the same affinity as the wild-type hormone, but it cannot stimulate the receptor and it acts as an antagonist. Such an EPO mutant has been described recently²⁶ and gives further evidence that EPO acts through homodimerization of its receptor.

Why are agonist antibodies for EPO-R so rare? All MoAbs specific to the extracellular domain should dimerize the receptor because they are bivalent. However, the vast majority of antibodies in our screen are not agonists (47 of 48) and form inactive 2:1 complexes. Although generation of specific MoAbs with antagonist activity has been reported previously,¹⁰⁻¹¹ agonist antibodies have not been described. Apparently, the cell surface imposes steric constraints and the two receptor subunits in the 2:1 complex have to be at a specific orientation and/or distance relative to each other. If this is not the case, receptor-receptor interactions necessary for signal transduction cannot be formed. Stimulation of EPO induces binding of a JAK2 kinase molecule to the cytosolic domain of each EPO-R molecule and increases phosphorylation of EPO-R and JAK2 kinase itself.²⁷ If the latter is an intermolecular phosphorylation process as has been described for receptor tyrosine kinases,^{28,29} close proximity of the two receptor molecules would be essential. Because of the size of the antibody, this proximity is unlikely in most antibody-receptor complexes. Since MoAb34 is a less potent agonist than EPO, it suggests that it dimerizes EPO-R in a slightly different way than the natural hormone does, and that this dimerization is suboptimal for signal transduction.

ACKNOWLEDGMENT

We thank Dr H. Lodish for providing the BaF3 cell line, Dr J. Winklermann for human EPO-R plasmid pLAP-37, Dr N. Kametani for the cell line UT-7/EPO, Dr T. Papayannopoulos for OCIM1 cells, and B. van Dyke for the antibody 2B12. We are grateful to Drs H. Lodish and D. Milligan for stimulating discussion.

REFERENCES

1. Krauss RS: Erythropoietin. *Blood* 77:419, 1991
2. Koury MJ, Bandurani MC: Erythropoietin: structure DNA break.

BEST AVAILABLE COPY

Application No. 10/071,962
Appeal Brief
Customer Number 26839
Attorney Docket No.: TNX98-03-01
Page 11 of 11

X. Related Proceedings Appendix

NONE